The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation  by Charni-Ben Tabassi, N. et al.
Osteoarthritis and Cartilage (2008) 16, 1183e1191
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2008.02.008
International
Cartilage
Repair
SocietyThe type II collagen fragments Helix-II and CTX-II reveal different
enzymatic pathways of human cartilage collagen degradation
N. Charni-Ben Tabassi Ph.D., Dr.ya, S. Desmarais Ph.D., Dr.za, A.-C. Bay-Jensen Ph.D. Studentx,
J. M. Delaisse´ Ph.D., Dr.x, M. D. Percival Ph.D., Dr.z and P. Garnero Ph.D., D.Sc., Dr.yk*
ySynarc, Molecular Markers, Lyon, France
zDepartment of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research,
Kirkland, Quebec, Canada
xClinical Cell Biology (KCB), Center for Research and Education in Health Science,
University of Southern Denmark, Vejle Hospital, Vejle, Denmark
k INSERM Research Unit 664, Lyon, France
Summary
Objective: Cartilage degradation in osteoarthritis (OA) generates the type II collagen fragments, Helix-II and CTX-II that can be used as clinical
biological markers. Helix-II and C-telopeptide of type II collagen (CTX-II) levels are associated independently with progression of OA suggest-
ing that they may be generated through different collagenolytic pathways. In this study we analyzed the release of Helix-II and CTX-II from
human cartilage collagen by the proteinases reported to play a role in cartilage degradation.
Methods: In vitro, human articular cartilage extract was incubated with activated human recombinant cathepsins (Cats) and matrix-metallopro-
teases (MMPs). Next, we analyzed the spontaneous release of Helix-II and CTX-II from cartilage sections of patients with knee OA who were
immediately deep frozen after joint replacement to preserve endogenous enzyme activity until assay. Cartilage sections were then incubated
for up to 84 h in the presence or absence of E-64 and GM6001, inhibitors of cysteine proteases and MMPs, respectively.
Results: In vitro, Cats K, L and S generated large amount of Helix-II, but not CTX-II. Cat B generated CTX-II fragment, but destroyed Helix-II
immunoreactivity. Cat D was unable to digest intact cartilage. MMPs-1, -3, -7, -9, and -13 efﬁciently released CTX-II, but only small amount of
Helix-II. Neither CTX-II nor Helix-II alone was able to reﬂect accurately the collagenolytic activity of Cats and MMPs as reﬂected by the release
of hydroxyproline. In OA cartilage explants, E-64 blunted the release of Helix-II whereas the release of CTX-II could be completely abrogated
by GM6001 and only partly by E-64.
Conclusion: These in vitro and ex vivo experiments of human cartilage suggest that Helix-II and CTX-II could be released in part by different
enzymatic pathways. Helix-II and CTX-II alone reﬂect only partially overall cartilage collagen degradation. These ﬁndings may explain why
these two biological markers could provide complementary information on disease progression in OA.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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One of the hallmarks of osteoarthritis (OA) is the destruction
of articular cartilage. The development of therapies that can
halt disease progression is currently hampered by our
inability to measure with adequate sensitivity the destruc-
tion of articular cartilage. Radiographic assessment of joint
space narrowing e an indirect index of cartilage loss e
requires measurements over a prolonged time (1e5 years)
and is prone to technical difﬁculties1. Conventional
laboratory tests such as C-reactive protein show inﬂamma-
tion in some patients but provide little information on joint
damage. Given the limitation of currently available investi-
gations, there has been considerable interest in exploringaBoth authors contributed equally to this work.
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1183the potentials of biological markers that reﬂect quantitative
and dynamic variations in joint tissue remodeling2e4.
Cartilage tissue mainly consists of type II collagen which
forms the ﬁbrillar structure of the extracellular matrix. Type II
collagen is constituted by the association of three identical
a1 chains in a triple helix except at the two ends, in the
N- and C-telopeptides. Proteolytic cleavage of type II
collagen involves several proteases including matrix-
metalloproteases (MMPs) and cathepsins (Cats) which
are synthesized by the chondrocytes and synovial cells in
response to cytokines and growth factors5e7. Current
evidence suggests that the initial steps in extra cellular
cartilage matrix breakdown involve degradation by the
collagenases, MMP-1, MMP-8, MMP-13 and MMP-14
which cleaves the triple helical region of type II collagen
at a single site between residues 775 and 776 generating
two fragments representing, respectively, 3/4 and 1/4 of
the intact collagen molecule8. These large fragments can
be subsequently degraded by other enzymes including
MMPs and cysteine proteases such as Cats K, L, S and
the aspartic protease Cat D9e11.
1184 N. C.-B. Tabassi et al.: Collagenolytic pathways in cartilageAmong the different biochemical markers of cartilage
breakdown, recent clinical studies suggest that the type
II collagen fragments, Helix-II and C-telopeptide of type
II collagen (CTX-II), could be useful for the clinical
investigation of patients with OA (for a review Ref. 12).
The urinary excretion of both Helix-II and CTX-II which
are derived from the helical and C-telopeptide portion of
type II collagen, respectively, have been shown to be
increased in patients with knee or hip OA and in patients
with rheumatoid arthritis (RA), higher levels being associ-
ated with an increased risk of radiological progres-
sion13e17. Both in OA and RA, it has been shown that
the urinary levels of Helix-II and CTX-II were only
moderately correlated and were associated indepen-
dently of each other with disease progression15,18. These
clinical data, suggest that Helix-II and CTX-II could reﬂect
in part different biological pathways of cartilage
degradation.
Sondergaard et al.19 investigated the relative contribution
of cysteine proteases and MMPs to the release of CTX-II
from cultured bovine cartilage explants stimulated by a com-
bination of the cytokines oncostatin M and tumor necrosis
factor-a (TNF-a). Using non-selective inhibitors, they
showed that inhibition of MMP activity reduces the release
of CTX-II in the culture medium, whereas the inhibition of
cysteine proteases tends to increase its levels. However,
the identity of the individual enzymes involved in the release
of CTX-II fragments was not systematically investigated.
Currently there is no information available on the relative
contribution of cysteine proteases and MMPs to the release
of Helix-II.
The aim of our study was to identify which enzyme(s) can
generate CTX-II and Helix-II using in vitro and ex vivo
models of human articular cartilage. Such data should
provide a better understanding of the mechanisms underly-
ing the complementary information provided by CTX-II and
Helix-II on disease progression in OA and RA.Materials and methodsSOURCES OF PROTEASESRecombinant human Cats K and L were prepared as previously
described20,21. The identity of Cats K and L was conﬁrmed by Western
Blot and by peptide substrate selectivity experiments. Additionally the
identity of Cat K was also conﬁrmed by the use of selective inhibitors as
previously described21. Purity of Cats K and L preparations was conﬁrmed
by gel-electrophoresis.
Recombinant human Cat S was from Calbiochem (La Jolla, CA, USA).
Human Cat B was purchased from Sigma-Aldrich (St-Louis, MO, USA).
Recombinant Cat D and recombinant human pro-MMP-1, -3, -7, -9 and -13
were purchased from R & D Systems (Minneapolis, MN, USA). Pro-MMPs
were activated with 1-mM 4-aminophenyl mercuric acetate (APMA) (Calbio-
chem) following supplier instructions. The concentration of active Cats was
determined by active site titration using E-64 (Sigma-Aldrich, St-Louis, MO,
USA), whereas that of MMPs was based on supplier information.COLLAGENOLYSIS OF HUMAN CARTILAGE IN VITROSuperﬁcial articular hip cartilage of a 19-year-old man was purchased
from Asterand (Detroit, MI, USA). The cartilage was ﬁnely ground in
a mill under liquid nitrogen. The cartilage powder was then incubated at
a concentration of 5 mg/mL in the presence of 1 mM of activated recombi-
nant human enzymes. For the investigation of the collagenolytic activity of
Cats the following assay buffers for optimal enzymatic activity were used:
100-mM sodium acetate pH 5.0, 2-mM ethylenediaminetetraacetic acid
(EDTA), 2-mM dithiotheritol (DTT) for Cats B, K and L; 100-mM sodium
phosphate pH 6.5, 2-mM EDTA, 2-mM DTT for Cat S, 100-mM sodium ac-
etate pH 3.5, 200-mM NaCl for Cat D. For MMPs, the incubation buffer
consisted of 50-mM Tris-HCl pH 7.5, 20-mM CaCl2, 150-mM NaCl, 2-M
ZnCl2, 0.05% Brij-35. All incubations were performed in duplicate for24 h at 37C under gentle agitation. Control experiments were performed
by incubating the cartilage powder in the corresponding buffer without pro-
teinases. After incubation, the reaction was stopped by 10 mM E-64
(Sigma-Aldrich, St-Louis, MO, USA) for Cats B, K, L, and S; 10 mM pepsta-
tin A for Cat D, and 50-mM EDTA for MMPs. The undigested cartilage
particles were removed by centrifugation (1500 g for 10 min) and the su-
pernatants were stored frozen at 80C until analysis (in duplicate) for hy-
droxyproline content and immunoassays for Helix-II and CTX-II. Enzyme
activity was veriﬁed at time 0, 4 h and 24 h using 2 ml of the reaction mix-
ture in 100-ml assay buffer in the presence of the following ﬂuorescent pep-
tide substrates: Z-L-R-AMC (2 mM, NovaBiochem, Darmstadt, Germany)
for Cats B, K, L and S, Mca-P-L-G-L-Dpa-A-R-NH2 (10 mM, R & D Sys-
tems, Minneapolis, MN, USA) for MMP-1, -7, -9, -13 and Cat D and
Mca-R-P-K-P-V-E-Nval-W-R-K(Dnp)-NH2 (10 mM, R & D Systems) for
MMP-3. We also performed successive incubations of Cat K and MMP-7
or MMP-13-generated fragments with MMPs and Cats, respectively. In
these studies, the 24-h Cat K and MMP-7 or MMP-13 digest supernatants
were stopped with E-64 and EDTA, respectively. The pH was adjusted to
the appropriate value for the second enzyme, and in the case of MMPs an
excess of CaCl2 was added to trap the EDTA present in the initial Cat K
buffer.
To determine cartilage collagen content and degradation, cartilage
powder and digest supernatants were hydrolyzed in 6-N HCl for 22 h at
110C and analyzed for hydroxyproline. Hydroxyproline concentration was
determined in a microtiter plate by a modiﬁed colorimetric assay using chlor-
amin-T and Ehrlich’s reagent (p-dimethyl-aminobenzaldehyde) according to
the method of Firschein and Shill22. Based on the assumption that 1 mg of
collagen contains 124-mg hydroxyproline, we found that 37% of the cartilage
powder consists of collagen, a proportion similar to that previously reported23.RELEASE OF THE TYPE II COLLAGEN FRAGMENTS HELIX-II
AND CTX-II IN EX VIVO MODEL OF HUMAN CARTILAGEBiopsies from cartilage explants taken from two female patients with
knee OA (age 62 and 64 years) undergoing total knee replacement were
cut out from the medial side of the tibial plateau, proximal to the lesion
site, snap frozen in O.C.T. medium (Sakura, ProHosp, Denmark)
immediately after surgery and stored at 80C. All biopsies showed similar
histological characteristics, including some ﬁbrillation, little cluster forma-
tion and tidemark alterations (Mankin score between 5 and 9). Sections
of 150 mm were cut from the biopsies, placed in a 24-well culture plate,
and washed twice with phosphate buffer saline (PBS) to remove freezing
medium and blood cells. Each section was then pre-incubated for 12 h
in adequate activation buffers (see below) for initial protease activation
at 37C under gentle agitation. After this activation of 12-h period, 100 ml
of supernatant was isolated from each well, centrifuged (1500 g) and
stored at 80C. One hundred microliters of fresh buffer containing either
no inhibitor or inhibitor for MMPs or cysteine proteases were then incu-
bated for an additional 24 h (total incubation time 36 h), 48 h (total 60 h)
or 72 h (total 84 h) at 37C under gentle agitation, in a humid chamber.
All incubations were done in triplicate.
To evaluate the endogenous activity of MMPs, cartilage sections were
incubated in a 50-mM Tris buffer (pH 7.5) containing 150-mM NaCl,
5-mM CaCl2, 0.05% Brij-35 and 0.2-mg NaN3/mL. Activation of latent
MMPs was performed by adding 1-mM freshly made APMA (Sigma-
Aldrich, Denmark), except for the control. MMP activity was inhibited by
the non-selective inhibitor, GM6001 (Chemicon, AHdiagnostics, Denmark)
at 10 mM. For investigating activity of endogenous cysteine proteases,
cartilage sections were incubated in 50-mM sodium acetate buffer (pH
5.5), containing 2-mM DTT, 5-mM EDTA and 0.2-mg NaN3/mL. Inhibition
was performed by adding 50-mM E-64 (Sigma-Aldrich, Denmark). At the
end of each incubation time, supernatant (about 400 ml) was isolated,
centrifuged (1500 g) and stored frozen at 80C until assay for hydroxy-
proline, Helix-II and CTX-II.
Use of postoperative knee cartilage samples was approved by the Danish
ethical committee.IMMUNOASSAYS FOR HELIX-II AND CTX-IIHelix-II was measured by a competitive enzyme linked immunosorbent
assay (ELISA) based on a rabbit polyclonal antibody raised against the
amino acid 622e632 sequence derived from the sequence of the a1 chain
of human type II collagen. This sequence is speciﬁc for type II collagen15. In-
tra and inter assay variations were lower than 8 and 13%, respectively15.
CTX-II was measured with a competitive ELISA (Cartilaps; Nordic Biosci-
ence, Herlev, Denmark) based on a mouse monoclonal antibody raised
against the EKGPDP sequence of human type II collagen C-telopeptide.
This sequence is speciﬁc for the CTX-II. Intra and inter assay variations
were lower than 8 and 15%, respectively24. All determinations were done
in duplicate.
1185Osteoarthritis and Cartilage Vol. 16, No. 10ResultsABILITY OF CATHEPSINS AND MMPs TO GENERATE HELIX-II
AND CTX-II FRAGMENTS IN VITROWe ﬁrst investigated to what extent Cats and MMPs can
solubilize collagen from human cartilage by measuring the
release of hydroxyproline in the supernatant. In preliminary
studies, we investigated the catalytic activity of Cats and
MMPs during the 24-h incubation period by analyzing an
aliquot of the reaction mixture before and after 4 and 24 h
of incubation using the synthetic peptides described in the
Material and methods as a substrate. For all MMPs and
Cats B and L, the catalytic activity after 4 and 24 h of incuba-
tion was very similar compared to initial activity (data not
shown). For Cats K and S, the catalytic activity observed after
4 h was similar to initial value, but after 24 h of incubation only
29 and 3%, respectively, of initial activity was observed. We
also performed time-course studies by incubating cartilage
powder for 0.5, 4, 24 and 48 h with MMPs and Cat K. There
was an increase in solubilization up to 24 h with no further
increase between 24 and 48 h (data not shown).
Among the different Cats, Cats Ke despite the decrease in
catalytic activity observed during incubatione and L were the
most efﬁcient to solubilize cartilage collagen (35% of solubili-
zation after 24 h), followed by Cats B and S (20%) whereas
Cat D was poorly efﬁcient [Fig. 1(A)]. MMP-13 efﬁciently
solubilized collagen (about 70% of collagen) [Fig. 1(B)].
MMPs-1, -3, -7 and -9 were also able to solubilize articular
collagen to some extent. Blank assays performed by incubat-
ing cartilage powder in buffer without proteases, but with
APMA to activate potential endogenous latent MMPs,
showed only very limited solubilization (less than 3%).
We then analyzed cartilage digests by ELISA for Helix-II
and CTX-II. Helix-II and CTX-II values were expressed in
nmol/mg of hydroxyproline released into the supernatant to
adjust for difference in collagen solubilization (Fig. 2).
Although most Cats and MMPs can solubilize cartilage
collagen, only speciﬁc subsets were able to generate
Helix-II and CTX-II immunoreactive fragments (Fig. 2).
Cats L and S released the largest amount of Helix-II immu-
noreactivity from cartilage collagen [Fig. 2(A)], whereas Cat
B was the only Cat able to release CTX-II [Fig. 2(B)]. Cat K
was able to generate small amount of Helix-II immunoreac-
tivity [Fig. 2(A)], but not CTX-II [Fig. 2(B)].
Because titration of MMPs was not performed, the
collagenolytic activity of the different enzymes could not0
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Fig. 1. Efﬁciency of Cat (A) and MMPs (B) to solubilize human articular c
24 h at 37C with 1 mM of activated recombinant human enzymes (see Ma
was evaluated by measuring hydroxyproline in the supernatant of each inc
of collagen present initially in the tube. The bars are the meanþSDbe directly compared. However, for each individual enzyme,
it was possible to compare its efﬁciency to release Helix-II
and CTX-II which were measured in the same test tube.
As shown on Fig. 2, all individual MMPs more efﬁciently
released CTX-II than Helix-II (Fig. 2).
We next performed sequential incubations to investigate
whether a combined action of Cats and MMPs could affect
Helix-II and CTX-II immunoreactivity initially released during
action of enzyme of native cartilage collagen. In these
subsequent digestions, we did not measure hydroxyproline
release in the supernatant and thus could not express the
data in nmol/mg of hydroxyproline. The objective of these
subsequent incubations was to explore whether the type II
collagen fragments initially released by Cats or MMPs can
be used as a substrate for further digestion which could
affect Helix-II or CTX-II immunoreactivity. We found that
the type II collagen fragments initially released by Cat K
were poor substrate for MMPs to generate Helix-II as the
concentration released in the supernatants was only slightly
higher than that of control incubation or slightly lower in the
case of MMP-1 [Fig. 3(A)]. In contrast Cat K-generated frag-
ments could be readily further processed by MMP-1 and
MMP-7 e but only to a small extent by MMP-3, -9 or -13 to
release CTX-II immunoreactive fragments [Fig. 3(B)]. We
then performed the reverse sequence of digestions by
sequentially incubating MMP-generated fragments with
Cats. In this experiment we used MMP-7 and MMP-13
digests as substrates for Cats, as the two preparations of
these enzymes appear to be most efﬁcient to solubilize the
cartilage. Whether fragments were generated by MMP-7 or
MMP-13 from cartilage powder, the release of CTX-II immu-
noreactivity could not be further enhanced by any of the Cats
[Fig. 4(C) and (D)]. Cat L seems actually to slightly decrease
CTX-II generated fragments from MMP-7 digestion. In con-
trast, the release of Helix-II immunoreactivity could be further
enhanced by Cat S and slightly by Cat L [Fig. 4(A) and (B)].
Conversely, Helix-II generated fragments from MMP-7 and
MMP-13 digests were destroyed by Cat B [Fig. 4(A) and (B)].EFFECT OF INHIBITION OF ENDOGENOUS ACTIVITY OF
CYSTEINE PROTEASES AND MMPs ON THE RELEASE OF
HELIX-II AND CTX-IITo investigate whether endogenous proteinases are able
to generate Helix-II and CTX-II in native tissues, we
measured Helix-II and CTX-II release in the supernatant0
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artilage collagen in vitro human cartilage powder was incubated for
terials and methods for details). The level of collagen solubilization
ubation mixture and was expressed as a percentage of the amount
of two different incubation experiments performed in duplicate.
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Fig. 2. Release of the type II collagen fragments Helix-II (A) and CTX-II (B) by Cats and MMPs from human cartilage collagen. Cartilage
powder was incubated as described in Fig. 1 and Helix-II and CTX-II were measured in the supernatant by ELISA. Helix-II and CTX-II values
were expressed in nmol/mg of hydroxyproline released in the supernatant. The bars are the meanþSD of two different incubation experiments
performed in duplicate.
1186 N. C.-B. Tabassi et al.: Collagenolytic pathways in cartilageof human cartilage explants taken from the knee of patients
with OA. The contribution of cysteine proteases and MMPs
was investigated by incubating slices from fresh frozen
human cartilage in the adequate buffer in the presence or
absence of E-64 or the general MMP inhibitor GM6001,0
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1187Osteoarthritis and Cartilage Vol. 16, No. 10collagen solubilization and to correct Helix-II and CTX-II
levels. After 84 h of incubation, about 20% of collagen
was solubilized both in cysteine and MMPs conditions.
This collagen degradation could be prevented by the
addition of the respective inhibitors (data not shown).
As shown on Fig. 5, compared to values observed after
the 12-h activation period, there was an increase of Helix-
II release with incubation time (up to 60 h) when cartilage
slices were incubated in a buffer favorable for cysteine
protease activity [Fig. 5(A)]. When the experiments were
performed in the presence of E-64, there was a decrease
of the release of Helix-II compared to baseline 12-h-values
and control experiments without inhibitor [Fig. 5(A)]. In
contrast, when cartilage slices were incubated in a buffer
favorable for MMPs, there was no change of Helix-II release
with time with or without GM6001 [Fig. 5(B)]. CTX-II release
increased with incubation time both in conditions favorable
for cysteine proteases [Fig. 5(C)] or MMPs [Fig. 5(D)]. The
time dependent release of CTX-II in MMP buffer was
completely prevented when experiments were performed
in the presence of GM6001 [Fig. 5(D)]. Addition of E-64 to
cartilage explants cultivated in a cysteine favorable buffer
also signiﬁcantly e but not completely e reduced the time
dependent release of CTX-II [Fig. 5(C)]. There was largevariability in the release of Helix-II and CTX-II probably
because of the limited number of slices investigated
(n¼ 3) at each time point and possible heterogeneity in
endogenous enzyme activity.Discussion
In this study we analyzed the possible enzymatic
pathways that can contribute to the release of the type II
collagen fragments, Helix-II and CTX-II, two biochemical
markers of cartilage degradation which have been recently
investigated for monitoring patients with arthritis. Using in
vitro and ex vivo models of human cartilage degradation,
we found that the enzymatic pathways involved in the
release of Helix-II and CTX-II are in part distinct and may
be complementary. In addition, it appears that Helix-II or
CTX-II alone could not reﬂect adequately the overall
collagenolytic activity of Cats and MMPs as measured by
hydroxyproline release. Thus, our data suggest that the
results of these two biological markers should be inter-
preted cautiously when used to assess patients with arthritis
and that their combination may provide complimentary
information on cartilage degradation.
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Fig. 5. Comparative effect of a cysteine proteinase inhibitor (E-64) (A, C) and an MMP inhibitor (GM6001) (B, D) on the release of Helix-II (A, B)
and CTX-II (C, D) in culture of human OA cartilage explants. Human cartilage sections were incubated in a buffer favorable to either cysteine
proteases or MMPs activity and in the presence (ﬁlled circle) or absence (open circle) of 50-mM E-64 or 10-mMGM6001 for 12, 36, 60 and 84 h.
All cartilage explants were initially pre-incubated for 12 h in absence of inhibitors to activate endogenous enzymes and then further incubated
for up to 72 h (total incubation time, 84 h) with or without protease inhibitors. At each time point, collagen content within the cartilage explant
was estimated by hydroxyproline determination. Supernatant was also analyzed at each time point and conditions for release of hydroxypro-
line, Helix-II and CTX-II (see Materials and methods for details). Levels of Helix-II and CTX-II were corrected for total collagen content
estimated from the sum of hydroxyproline within the cartilage explants and the supernatant. Helix-II and CTX-II values after 36, 60 and
84 h of incubation were then expressed in percent of the values of the 12 h activation period. Paired cartilage explants from the same patient
were used in each incubation condition (for example, MMP buffer with or without inhibitor and/or APMA). Each bar represents the mean
valueþSD of duplicate incubations from three consecutive cartilage sections taken vertically from the same cartilage explant. The P values
analysis of variance (ANOVA) refer to the difference in the time dependent changes of Helix-II and CTX-II release between experiments
performed with and without enzyme inhibitors.
1188 N. C.-B. Tabassi et al.: Collagenolytic pathways in cartilageIn vitro, we used the cysteine proteases and the MMPs
which have all been suggested to play a role in the degra-
dation of cartilage matrix in pathological conditions6,8,25.
Using the release of hydroxyproline which provides a global
index of collagen degradation, we conﬁrmed that among
the various cysteine proteases, Cats K26 and L27 exhibited
the highest collagenolytic activity, whereas Cats B and S
have low efﬁciency and Cat D e an aspartic protease e
could not digest intact articular cartilage. The high collage-
nolytic activity of Cat K on cartilage collagen is in agree-
ment with recent studies performed on bovine cartilage11
and results from its unique feature of cleaving not only
the telopeptides e a property which is common to all cyste-
ine proteases e but it can also attack the triple helix at mul-
tiple sites26. The relevance of investigating Cat K in arthritis
diseases has also been recently suggested by studies
showing increased expression of this enzyme in the syno-
vial membrane of patients with RA28,29 and in OA carti-
lage30. For MMPs, our in vitro experiments are also in
agreement with previous studies showing a high potency
of MMP-13 to solubilize cartilage collagen8. The other
MMPs including the collagenase MMP-1, the gelatinase
MMP-9, stromelysin-1 (MMP-3) and the matrilysin 1
(MMP-7) had lower collagenolytic activity at 37C.
For CTX-II, in vitro experiments showed that only one
cysteine protease, namely Cat B, could release this peptide
from intact type II collagen, whereas all MMPs tested,
especially MMP-9 and MMP-13 have this ability. Thesedata are in agreement with a recent study using bovine
cartilage showing that CTX-II was efﬁciently released by
MMP-9 and -13, but not Cat K19. Our sequential incubations
indicate, however, that large non-CTX-II immunoreactive
collagen fragments initially generated by Cat K when further
processed by some MMPs can release some CTX-II
immunoreactivity. We also show for the ﬁrst time that
Cat B, a cysteine protease which has been shown to be
over-expressed in OA cartilage31, can release signiﬁcant
amount of CTX-II directly from human cartilage collagen,
suggesting a potential cleavage site of this enzyme within
the C-telopeptide region (Fig. 6).
Our study is the ﬁrst to investigate the potential enzymatic
pathways involved in the generation of Helix-II. In vitro
experiments showed that this type II collagen fragment could
be released from cartilage matrix by several cysteine prote-
ases including Cats L and S, and to a lower extent Cat K
(Fig. 6). Although all MMPs e but MMP-13 e could gener-
ated some Helix-II immunoreactivity, for each individual en-
zyme the release of Helix-II was lower than that of CTX-II.
The fact that Helix-II can be directly released by Cat L, Cat
S, MMP-3 and MMP-7 is of biological relevance as all these
enzymes have been implicated in cartilage degradation in
OA and RA8,29,32. Cat S released large amount of Helix-II im-
munoreactive peptides, although it has been originally de-
scribed as a non-helical telopeptides degrading enzyme33.
More recently, a moderate triple helical collagenolytic activ-
ity of Cat S has been reported on bovine cartilage collagen at
N-telopeptide
Major triple helix
C-telopeptide
APGERGETGPPGTSGIA
GPPGPGIDMSAFAGLGPR LQYMRA
MMP-1, 3, 7, 9, 13
Cat B
Cat K, L, S
MMP-3, 7, -9
GPQGLAG
MMP-1,-8,-13,-14
¾ cleavage1
Helix-II
EKGPDP
CTX-II
Destruction by Cat B of C-terminal 
immnoreactive Helix-II epitope
Fig. 6. Schematic representation of a type II collagen molecule and
localization of the sequence of the biochemical markers Helix-II and
CTX-II and of the enzymatic cleavage sites involved in their
generation. In bold italic font are the sites determined in the present
study. For Cat B in the Helix-II sequence, the exact site was not
determined. 1Site reported by Billinghurst et al.36; 2sites reported
by Lohmander et al.37
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affected by the concentration of glycosaminoglycan within
the matrix11. Our sequential incubation experiments show-
ing that when initially cleaved by MMP-7, a secondary cleav-
age of collagen fragments by Cat B abrogated Helix-II
immunoreactivity, suggest a potential cleavage site of this
enzyme within the sequence of the Helix-II epitope
(Fig. 6). This ﬁnding also suggests that in situation where
Cat B is highly active, the releases of CTX-II and Helix-II
are mutually exclusive.
Results of the in vitro experiments should be interpreted
cautiously. Because titration of the different MMPs was
not formally assessed using tissue inhibitor of MMP
(TIMP), we could not directly compare the efﬁcacy of the
various enzymes to generate Helix-II and CTX-II, although
comparison of each enzyme considered individually is still
valid. MMP-13 has a high gelatinolytic activity (in addition
to its high collagenolytic properties) compared to other
MMPs such as MMP-1. Thus, the absence of Helix-II
release with MMP-13 may reﬂect either a true inefﬁciency
of this enzyme to generate Helix-II from intact collagen
and/or its activity to further degrade larger collagen frag-
ments into smaller non-immunoreactive species. This
situation was actually observed with Cat B which abrogated
Helix-II immunoreactive in the sequential incubation exper-
iments. Finally, we used cartilage powder from a young
individual characterized by active remodeling and contain-
ing probably a mixture of intact and denaturated collagen.
Thus, our data may not be representative of the activity of
Cats and MMPs on intact crosslinked triple helical collagen.
However, in vivo, cartilage from patients with OA is likely to
contain not only intact collagen, but also several
populations of denaturated collagen molecules.
We also investigated the relative contribution of cysteine
proteases and MMPs to generate Helix-II and CTX-II
peptides using ex vivo cartilage explants from patients
with OA. We selected to use fresh sections of cartilage
which were deep frozen just after surgery until being
incubated. This system has several advantages. It employs
human samples from patients with OA avoiding any
potential issues related to species speciﬁc effects on
enzyme activity as this has been reported, for example,for Cat B34. We also observed species difference for Cat
K in preliminary studies. Indeed, although both rabbit and
human Cat K were able to efﬁciently solubilize rabbit and
human cartilage as assessed by hydroxyproline release,
CTX-II could be released only from rabbit but not from
human cartilage (unpublished observations). Moreover, as
sections are frozen before the experiments, cells are not
alive and thus only the effects of endogenous enzymes
synthesized within physiological conditions are analyzed.
This situation differs from systems using healthy non-
human cartilage in which cells are alive and stimulated
with catabolic factors such as oncostatin M and TNF-a35.
The phenotype of chondrocytes in these culture conditions
may be altered compared to physiological conditions.
However, this ex vivo model has also limitations. Because
enzymes can be artiﬁcially released by cells during the
freezingethawing process, the assessed collagenolytic
activity may represent not only the extracellular degradation
machinery, but also lysosomial activity for cysteine prote-
ases. Consequently, we believe that these two ex vivo
models of cartilage are likely to provide complementary
information on the enzymatic process of tissue degradation.
The ex vivo data obtained indicated that Helix-II can be
released when tissue is incubated in a buffer favorable for
cysteine protease activity whereas no release could be
observed in conditions optimal for MMPs activity. The
selectivity for cysteine protease involvement was conﬁrmed
by the complete inhibition of Helix-II release when incuba-
tions were performed in presence of E-64. These data are
in part in agreement with the in vitro experiments showing
that Cats L and S efﬁciently released Helix-II peptides
from human cartilage powder. We could not observe any
signiﬁcant release of Helix-II when cartilage explants were
incubated at neutral pH, although our in vitro experiments
indicated that some MMPs could generate slight Helix-II
immunoreactivity. This apparent discrepancy could be
explained by the fact that in OA cartilage explants, MMPs
other than MMP-1, MMP-3, MMP-7 and MMP-9 e which
were able to release Helix-II in vitro e could contribute to
overall MMP activity. One possible candidate is MMP-1336
which was not able to generate Helix-II immunoreactivity
in vitro. We found that CTX-II can be generated by cartilage
explants both in conditions allowing cysteine protease and
MMPs activity. It should, however, be mentioned that
E-64 only partially prevented the time dependent increase
of CTX-II, suggesting some unspeciﬁc release during cyste-
ine proteases conditions. In contrast, GM6001 an inhibitor
of MMPs could completely abrogated the time dependent
increase of CTX-II in agreement with previous studies using
bovine cartilage explants19. The release of CTX-II ex vivo
seems to be more important in cysteine protease compared
to MMPs conditions which may appear in disagreement with
the in vitro data. However, when subtracting unspeciﬁc
release observed in the presence of inhibitors, the magni-
tude of CTX-II increase was similar in both experimental
conditions. In addition because there was a large variability
in the ex vivo results, direct comparison between the two
conditions is difﬁcult.
One could argue that the conditions used to analyze the
contribution of Cats to Helix-II and CTX-II immunoreactivity
in these in vitro and ex vivo experiments do not reﬂect phys-
iological conditions of extracellular cartilage degradation.
However, the main objective of this study was to analyze
which enzymes previously described to be involved in
arthritis cartilage degradation could generate Helix-II and
CTX-II immunoreactivity in optimal conditions for their
activity independent of their tissue origin or compartment
1190 N. C.-B. Tabassi et al.: Collagenolytic pathways in cartilagecell localization. For example, synovial ﬁbroblasts from
patients with RA highly express Cat K which has been
shown to actively participate in the intracellular degradation
of type II collagen28. Thus, it is possible that after the initial
extracellular cartilage degradation by MMPs, some large
type II collagen fragments could be endocytosed by syno-
vial ﬁbroblasts and further degraded by lysosomial
cysteine proteases at acidic pH. In that respect our sequen-
tial in vitro incubations indicating that collagen fragments
initially released from cartilage matrix by MMPs can be
further processed by Cats to increase or decrease Helix-II
immunoreactivity are relevant to this proteolytic mechanism.
In addition, a participation of Cats in extracellular matrix
degradation may also be possible as it has been shown
that the pH of superﬁcial ﬁbrillated cartilage matrix from
patients with severe OA can be as low as 5.530 which is
the pH value used in our ex vivo experiments to analyze
the contribution of cysteine proteases. Finally Cat S is
also active at neutral and slightly alkaline pH33 and thus
may participate in the extracellular generation of Helix-II
immunoreactivity.
Our in vitro experiments showed that the overall collage-
nolytic efﬁcacy of the enzymes assessed by hydroxyproline
release was not accurately reﬂected by either Helix-II or
CTX-II taken individually. Indeed, MMP-13 and Cats K
and L appeared to be most efﬁcient collagenolytic enzymes
(Fig. 1) but CTX-II was released only by MMP-13 and not by
these Cats [Fig. 2(B)]. Conversely, Helix-II immunoreactivity
could not be detected in the presence of MMP-13, but was
efﬁciently by Cat L and to a lower extent Cat K [Fig. 2(A)].
Thus, the combined use of Helix-II and CTX-II may provide
a more accurate indication of the overall type II collagen
degradation than one of these two markers alone. However,
because, it is impossible to predict which combinations of
these proteases occur in vivo and at which sites within
the tissue, one, however, cannot conclude from these in
vitro experiments whether Helix-II or CTX-II reﬂects more
adequately the collagenolysis occurring in vivo.
In summary, using in vitro and ex vivo models of human
cartilage degradation, we showed that the biological markers
Helix-II and CTX-II could be released in part by different and
potentially complementary enzymatic pathways. In vivo, we
can hypothesize that Helix-II and CTX-II may reﬂect differen-
tial collagen degradation pathways, depending on the
prevailing proteinases in different cartilage areas or joint
tissues, and/or on the stage of the disease process, and/or
the individual patient. Our ﬁndings may provide some
possible mechanistic basis for the added value of Helix-II
and CTX-II to predict disease progression in OA and RA.Conﬂict of interest
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